1
|
Sehner C, Bernier T, Blum K, Clemann N, Glogovac M, Hawkins WA, Kohan M, Linker F, Lovsin-Barle E, Osadolor O, Pfister T, Schulze E, Schwind M, Tuschl G, Wiesner L. Comparison of permitted daily exposure (PDE) values for active pharmaceutical ingredients (APIs) - Evidence of a robust approach. Regul Toxicol Pharmacol 2024; 150:105649. [PMID: 38782234 DOI: 10.1016/j.yrtph.2024.105649] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2023] [Revised: 03/20/2024] [Accepted: 05/20/2024] [Indexed: 05/25/2024]
Abstract
Permitted Daily Exposure Limits (PDEs) are set for Active Pharmaceutical Ingredients (APIs) to control cross-contamination when manufacturing medicinal products in shared facilities. With the lack of official PDE lists for pharmaceuticals, PDEs have to be set by each company separately. Although general rules and guidelines for the setting of PDEs exist, inter-company variations in the setting of PDEs occur and are considered acceptable within a certain range. To evaluate the robustness of the PDE approach between different pharmaceutical companies, data on PDE setting of five marketed APIs (amlodipine, hydrochlorothiazide, metformin, morphine, and omeprazole) were collected and compared. Findings show that the variability between PDE values is within acceptable ranges (below 10-fold) for all compounds, with the highest difference for morphine due to different Point of Departures (PODs) and Adjustment Factors (AFs). Factors of PDE variability identified and further discussed are: (1) availability of data, (2) selection of POD, (3) assignment of AFs, (4) route-to-route extrapolation, and (5) expert judgement and differences in company policies. We conclude that the investigated PDE methods and calculations are robust and scientifically defensible. Additionally, we provide further recommendations to harmonize PDE calculation approaches across the pharmaceutical industry.
Collapse
Affiliation(s)
- Claudia Sehner
- Boehringer Ingelheim Pharma GmbH & Co. KG, 88397, Biberach, Germany.
| | - Tanja Bernier
- Abbott Laboratories GmbH, 31535, Neustadt Am Rübenberge, Germany
| | - Kamila Blum
- GlaxoSmithKline, Prinzregentenplatz 9, 81675, Munich, Germany
| | | | | | - William A Hawkins
- SafeBridge Europe Ltd., 33 St Andrews Street South, Bury St Edmunds, IP33 3PH, Suffolk, United Kingdom
| | - Martin Kohan
- SafeBridge Europe Ltd., 33 St Andrews Street South, Bury St Edmunds, IP33 3PH, Suffolk, United Kingdom
| | - Fenneke Linker
- Grünenthal GmbH, Zieglerstraße 6, 52078, Aachen, Germany
| | | | - Osahon Osadolor
- AstraZeneca, Francis Crick Avenue, Cambridge, United Kingdom
| | | | - Elisa Schulze
- Merck Healthcare KGaA, Frankfurter Str. 250, 64293, Darmstadt, Germany
| | - Markus Schwind
- Sanofi-Aventis Deutschland GmbH, 65926, Frankfurt, Germany
| | - Gregor Tuschl
- Merck Healthcare KGaA, Frankfurter Str. 250, 64293, Darmstadt, Germany
| | - Lisa Wiesner
- Takeda Pharmaceuticals International AG, Glattpark-Opfikon, Switzerland
| |
Collapse
|
2
|
Blum K, FitzGerald R, Wilks MF, Barle EL, Hopf NB. Use of the benchmark-dose (BMD) approach to derive occupational exposure limits (OELs) for genotoxic carcinogens: N-nitrosamines. J Appl Toxicol 2023. [PMID: 36840679 DOI: 10.1002/jat.4455] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2022] [Revised: 01/29/2023] [Accepted: 02/21/2023] [Indexed: 02/26/2023]
Abstract
N-Nitrosamines are potent carcinogens and considered non-threshold carcinogens in various regulatory domains. However, recent data indicate the existence of a threshold for genotoxicity, which can be adequately demonstrated. This aspect has a critical impact on selecting the methodology that is applied to derive occupational exposure limits (OELs). OELs are used to protect workers potentially exposed to various chemicals by supporting the selection of appropriate control measures and ultimately reducing the risk of occupational cancer. Occupational exposures to nitrosamines occur during manufacturing processes, mainly in the rubber and chemical industry. The present study derives OELs for inhaled N-nitrosamines, employing the benchmark dose (BMD) approach if data are adequate and read-across for nitrosamines without adequate data. Additionally, benchmark dose lower confidence limit (BMDL) is preferred and more suitable point-of-departure (PoD) to calculate human health guidance values, including OEL. The lowest OEL (0.2 μg/m3 ) was derived for nitrosodiethylamine (NDEA), and nitrosopiperidine (NPIP) (OEL = 0.2 μg/m3 ), followed by nitrosopyrrolidine (NPYR) (0.4 μg/m3 ), nitrosodimethylamine (NDMA), nitrosodimethylamine (NMEA), and nitrosodipropylamine (NDPA) (0.5 μg/m3 ), nitrosomorpholine (NMOR) (OEL = 1 μg/m3 ), and nitrosodibutylamine (NDBA) (OEL = 2.5 μg/m3 ). Limits based on "non-threshold" TD50 slope calculation were within a 10-fold range. These proposed OELs do not consider skin absorption of nitrosamines, which is also a possible route of entry into the body, nor oral or other environmental sources. Furthermore, we recommend setting a limit for total nitrosamines based on the occupational exposure scenario and potency of components.
Collapse
Affiliation(s)
- Kamila Blum
- Environment, Health & Safety Department, GlaxoSmithKline, Munich, Germany.,Faculty of Science and Medicine, University of Geneva, Switzerland
| | - Rex FitzGerald
- Swiss Centre for Applied Human Toxicology (SCAHT) & Department of Pharmaceutical Sciences, University of Basel, Switzerland
| | - Martin F Wilks
- Swiss Centre for Applied Human Toxicology (SCAHT) & Department of Pharmaceutical Sciences, University of Basel, Switzerland
| | | | - Nancy B Hopf
- Swiss Centre for Applied Human Toxicology (SCAHT) & Department of Pharmaceutical Sciences, University of Basel, Switzerland.,Department for Occupational and Environmental Health, Centre for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland
| |
Collapse
|
3
|
Gouveia TIA, Mota IH, Silva AMT, Alves A, Santos MSF. Are cytostatic drugs in surface waters a potential threat? THE SCIENCE OF THE TOTAL ENVIRONMENT 2022; 853:158559. [PMID: 36087660 DOI: 10.1016/j.scitotenv.2022.158559] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/23/2022] [Revised: 08/23/2022] [Accepted: 09/02/2022] [Indexed: 06/15/2023]
Abstract
Cytostatic drugs are pharmaceuticals administered to cancer patients under chemotherapy. Their occurrence in surface waters has been reported worldwide, increasing environmental and human health concerns. This work addresses a question of worldwide interest: are these hazardous pharmaceuticals in surface waters a potential threat? For the first time, this study brings information on the presence of cytostatic drugs in Portuguese rivers. Furthermore, cutting-edge data on the occurrence of two cytostatic drugs is provided; up to the authors' best knowledge, flutamide and mycophenolate mofetil have never been monitored in worldwide surface waters. Nine out of thirteen cytostatic drugs were detected in Portuguese rivers. Despite bicalutamide being the cytostatic most frequently detected, the highest concentration was recorded for cyproterone (19 ± 3 ng/L). Three different scenarios were considered to estimate the risks from the exposure of humans to cytostatic drugs via surface waters. Two scenarios are associated with bathing practices in rivers, particularly in the spring and summer seasons (river beaches): (i) the exposure to cytostatic drugs by dermal contact with contaminated water and (ii) the exposure by accidental ingestion of contaminated water, which is less likely but also occurs. The third exposure scenario is related to (iii) the long-life consumption of drinking water produced from river water capture, under worst-case conditions, i.e. negligible degradation of cytostatic drugs at drinking water treatment plants. It was concluded that the third exposure context to cytostatics could represent a risk to children, if the highest concentration ever reported in the literature for cyclophosphamide in surface waters is considered. Still, attending to the carcinogenicity of some of these compounds (e.g., cyclophosphamide, chlorambucil, etoposide and tamoxifen), health risks might always be expected, regardless of the contamination level. Furthermore, health risks associated with synergic effects and/or long-term exposures cannot be ruled out, even for the remaining cytostatics/exposure contexts.
Collapse
Affiliation(s)
- Teresa I A Gouveia
- LEPABE - Laboratory for Process, Environmental, Biotechnology and Energy Engineering, Faculty of Engineering, University of Porto, R. Dr. Roberto Frias, 4200-465 Porto, Portugal; ALiCE - Associate Laboratory in Chemical Engineering, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, 4200-465 Porto, Portugal
| | - Isabel H Mota
- LEPABE - Laboratory for Process, Environmental, Biotechnology and Energy Engineering, Faculty of Engineering, University of Porto, R. Dr. Roberto Frias, 4200-465 Porto, Portugal; ALiCE - Associate Laboratory in Chemical Engineering, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, 4200-465 Porto, Portugal
| | - Adrián M T Silva
- ALiCE - Associate Laboratory in Chemical Engineering, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, 4200-465 Porto, Portugal; LSRE-LCM - Laboratory of Separation and Reaction Engineering - Laboratory of Catalysis and Materials, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, 4200-465 Porto, Portugal
| | - Arminda Alves
- LEPABE - Laboratory for Process, Environmental, Biotechnology and Energy Engineering, Faculty of Engineering, University of Porto, R. Dr. Roberto Frias, 4200-465 Porto, Portugal; ALiCE - Associate Laboratory in Chemical Engineering, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, 4200-465 Porto, Portugal
| | - Mónica S F Santos
- LEPABE - Laboratory for Process, Environmental, Biotechnology and Energy Engineering, Faculty of Engineering, University of Porto, R. Dr. Roberto Frias, 4200-465 Porto, Portugal; ALiCE - Associate Laboratory in Chemical Engineering, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, 4200-465 Porto, Portugal.
| |
Collapse
|
4
|
Ahuja V, Krishnappa M. Approaches for setting occupational exposure limits in the pharmaceutical industry. J Appl Toxicol 2021; 42:154-167. [PMID: 34254327 DOI: 10.1002/jat.4218] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2021] [Revised: 06/26/2021] [Accepted: 06/26/2021] [Indexed: 11/09/2022]
Abstract
The use of pharmaceutical drugs has provided a cure for many diseases. However, unintended exposure to drugs in the manufacturing workplace can cause significant health hazards to workers. It is important to protect the workforce from these deleterious effects by limiting exposure to an acceptable level, the occupational exposure limit (OEL). OEL is defined as airborne concentrations (expressed as a time-weighted average for a conventional 8-h workday and a 40-h work week) of a substance to which nearly all workers may be repeatedly exposed (for a working lifetime) without adverse effects. Determination of OELs has become very challenging over time, requiring an overall assessment of the preclinical and clinical data of the drug being manufactured. Previously, to derive OEL values, toxicologists used animal no-observed-adverse-effect level (NOAEL) data, which have been replaced with the overall assessment of animal and human data, placing a higher emphasis on human health-based data. A major advantage of working with human pharmaceuticals is that sufficient clinical data are available for them in most cases. The present manuscript reviews the latest knowledge regarding the derivation of occupational exposure limits as health-based exposure limits (HBELs) for pharmaceuticals. We have provided examples of OEL calculations for various drugs including levofloxacin (CAS No. 100986-85-4), dienogest (CAS no. 65928-58-7), and acetylsalicylic acid (ASA, CAS no. 50-78-2) using human data. This report will benefit professionals in the OEL domain in understanding this highly important, growing, and challenging field.
Collapse
Affiliation(s)
- Varun Ahuja
- Safety Assessment Department, Syngene International Limited, Bangalore, India
| | - Mohan Krishnappa
- Safety Assessment Department, Syngene International Limited, Bangalore, India
| |
Collapse
|